Zydus Cadila COVID-19 vaccine to get emergency use approval this week: Report

Zydus Cadila's jab will be the sixth COVID-19 vaccine to get approved in India after Covishield, Covaxin, Sputnik V, Moderna and J&J.

Moneycontrol News
August 10, 2021 / 08:28 AM IST

Zydus Cadila's jab will be the sixth COVID-19 vaccine to get approved in India after Covishield, Covaxin, Sputnik V, Moderna and J&J.

In what will be the first COVID-19 jab for the adolescent population in India, the Zydus Cadila vaccine is likely to get a nod from the Centre soon.

ZyCoV-D is likely to get an emergency use authorisation this week, sources told ANI.

Click here for LIVE updates on coronavirus pandemic

Zydus Cadila's jab will be the sixth COVID-19 vaccine to get approved in India after Covishield, Covaxin, Sputnik V, Moderna and J&J, which was the latest to get DGCI nod on August 7.

Zyduc Cadila had on July 1 said that it filed an application with the Drug Controller General of India (DCGI) seeking emergency use authorisation (EUA) of ZyCoV-D. It pans to manufacture 10-12 crore doses annually.

COVID-19 Vaccine

Frequently Asked Questions

View more
How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.

View more
Show

The company had said its COVID-19 vaccine ZyCoV-D demonstrated 66.6 percent efficacy against symptomatic RT-PCR positive cases in the interim analysis. It has also told the DGCI that ZyCoV-D is safe for children aged 12 to 18 years.

It is a three-dose, intradermal vaccine which is applied using the PharmaJet needle-free system. It can be stored at 2-8 degree Celsius but has shown good stability at temperatures of 25 degree Celsius for at least three months.

The Centre had on June 27 in an affidavit told the Supreme Court that Zydus Cadila’s vaccine candidate, "will be available for 12-18 age group soon, subject to the statutory permissions".

It informed the court that Zydus Cadila, which is developing DNA vaccines, has concluded its clinical trial for between the age group of 12 to 18 years of age. "Subject to the statutory permissions, it may be available in near future for children of the age group of 12 to 18 years of age," it added.

Click here for Moneycontrol's full coverage of COVID-19
Moneycontrol News
Tags: #coronavirus #COVID-19 vaccine #Health #India #Zydus Cadila
first published: Aug 10, 2021 08:28 am